At-a-Glance:| Company | BrainVTA |
|---|
| Specialties | Viral vectors, neuronal tracers, CRO/CDMO services |
|---|
| Mission | BrainVTA provides viral vector tools and research services to accelerate discovery in neuroscience and gene therapy. Founded by scientists who experienced firsthand the difficulty of obtaining reliable viral vectors for brain research, the company is committed to bridging the gap between basic research and clinical application. |
|---|
| Noteworthy | The company reports its tools have contributed to more than 1,300 peer-reviewed publications. |
|---|
| Location | Wuhan, China |
|---|
| CEO | Xiaobin He |
|---|
BrainVTA was founded in 2014 by scientists with backgrounds in neuroscience and virology who had experienced firsthand the difficulty of obtaining reliable, high-quality viral vectors for brain research. That bottleneck, they believed, was slowing discovery. The company was built around addressing it.
Over the past decade, BrainVTA has grown into a leading developer, manufacturer, and service provider of viral vector tools for academic institutions, government research organizations, and the pharmaceutical and biotechnology industries. The company's products and services support researchers working across neural circuit mapping, gene function studies, optogenetics, chemogenetics, calcium imaging, as well as in the development of treatments for neurological diseases, cancer, and genetic disorders.
The core product portfolio includes AAV and lentivirus vectors—available both as off-the-shelf and custom options—configured for gene overexpression, knockdown via shRNA, and gene editing using CRISPR/Cas9. BrainVTA also supplies specialized neuronal tracing viruses, including pseudorabies virus, herpes simplex virus, and vesicular stomatitis virus, for research-grade applications. For disease modeling, the company offers ready-to-use viral tools designed to support the construction of models for conditions such as Alzheimer's disease, Parkinson's disease, metabolic disorders, and cancer.
What distinguishes BrainVTA from reagent-only suppliers is its integrated approach to moving projects along the research-to-therapy continuum. The company offers a full range of CRO and CDMO services, covering everything from early-stage discovery through preclinical development to clinical-scale manufacturing. This includes cGMP-compliant AAV production capabilities, which allows BrainVTA to support biopharma partners pursuing IND-enabling studies and beyond.
A key part of that manufacturing capability is the proprietary One-Bac 4.0 insect baculovirus platform, developed to address limitations in yield, cost, and scalability associated with traditional mammalian cell-based AAV production systems. The platform is designed to produce high yields of AAV with improved quality attributes at industrial scale.
BrainVTA is also actively investing in capsid discovery and vector engineering, working to develop next-generation vectors with refined tropism, reduced immunogenicity, and improved delivery efficiency. The goal is not only to produce vectors for current research and therapeutic applications but to advance the underlying technology itself.
To date, the company reports having supported more than 200 pharmaceutical companies and over 3,000 research groups worldwide, with its tools referenced in more than 1,300 peer-reviewed publications. Looking ahead, BrainVTA has stated its ambition to move from being a supplier of research tools to serving as an integrated platform for the broader gene therapy ecosystem—with the goal of making the path from viral vector construct to clinical-grade therapy more efficient and accessible for developers worldwide.